Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fulcrum Therapeutics Inc FULC

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX... see more

Recent & Breaking News (NDAQ:FULC)

Shareholders In Fulcrum Therapeutics Inc Are Invited To Join The Schall Law Firm's Investigation Into Possible Securities Fraud

ACCESS Newswire September 14, 2024

The Schall Law Firm Is Looking Into Fulcrum Therapeutics, Inc. For Possible Securities Related Infractions And Impacted Investors Should Reach Out

ACCESS Newswire September 13, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 13, 2024

Fulcrum Therapeutics, Inc. (FULC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

ACCESS Newswire September 13, 2024

ATTENTION FULC SHAREHOLDERS: Investors Who Lost Money on Fulcrum Therapeutics, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

ACCESS Newswire September 13, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Reach Out

ACCESS Newswire September 13, 2024

Fulcrum Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - FULC

ACCESS Newswire September 12, 2024

Fulcrum Therapeutics Inc May Have Violated Securities Laws And Stockholders Are Invited By The Schall Law Firm To Help With An Inquiry

ACCESS Newswire September 12, 2024

Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - FULC

ACCESS Newswire September 12, 2024

FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Business Wire September 12, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc.(FULC) And Encourages Stockholders to Reach Out

ACCESS Newswire September 12, 2024

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

GlobeNewswire September 12, 2024

Fulcrum Therapeutics to Participate in Upcoming September Conferences

GlobeNewswire August 27, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 23, 2024

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

GlobeNewswire August 19, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 9, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

GlobeNewswire July 31, 2024

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

GlobeNewswire July 24, 2024

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

GlobeNewswire June 12, 2024

Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference

GlobeNewswire June 6, 2024